Webinars and Commercial Conversations — Register Now

Tuesday, December 1, 2026, 1 PM-2 PM ET

Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.

Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, January 12, 2027, 2 PM-3 PM ET
Hear Dr. Roden discuss how computational pathology will impact the practice & future of precision oncology, using global real world analytical evidence for the novel TROP2 NMR biomarker as an example.

Webinar presenter Anja C. Roden, MD, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science, Rochester, Minnesota

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Roche Diagnostics. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

September 2026

One for all: HER2 guidebook for solid tumors

September 2026—Though it may test the memory of many, there once was a time when HER2 immunohistochemistry was a relatively uncomplicated matter. Back in September 1998, the FDA approved both trastuzumab (Herceptin) and the first companion diagnostic assay, HercepTest, which was used to determine whether patients with metastatic breast cancer could receive the new drug.

What to consider in reporting germline VUS

September 2026—When Heidi Rehm, PhD, and other researchers examined more than 1.5 million diagnostic sequencing test results from 19 clinical laboratories, they found an astonishing rate of inconclusive reports due to variants of uncertain significance—nearly a third in diagnostic multigene panel testing.

Close-up on amyloid detection and fibril typing

September 2026—Amyloidosis has become a treatable disease—if the fibril type is identified accurately and quickly. That and the variability seen in its workup and diagnosis were the impetus for the recently published CAP amyloidosis guideline. The co-chairs of the guideline expert panel provided, in a CAP25 session, what they described as their own tips and tricks for amyloid detection and fibril typing, reported here.

AI, privacy, and pathology practice: HIPAA loophole and the need for caution

September 2026—Technology and regulation have always co-evolved, and artificial intelligence should be no exception. “The tech industry would have Americans believe there should be no regulation of anything that has AI in its title until such time as the technology is fully matured and ready to be regulated,” says Brian R. Jackson, MD, MS, professor of pathology, director of clinical pathology, and CLIA director of laboratories, University of Maryland Medical Center. He calls it “complete gaslighting.”

DPA leaders on digitization, AI, and deployment

September 2026—What do leaders of the Digital Pathology Association have to say about where digital pathology stands now and what to expect from AI? Six DPA leaders met online July 24 with CAP TODAY publisher Bob McGonnagle to talk about the technology and the tools. Many patients still don’t understand pathology’s role, said Orly Ardon, PhD, MBA, of Memorial Sloan Kettering Cancer Center, “and AI can create additional concerns if it is not explained properly.”

AMP case report: Is undifferentiated sarcoma with EWSR1-POU5F1 fusion a molecularly defined entity?

September 2026—About 30 percent of soft tissue sarcomas are associated with chromosomal translocations leading to the formation of chimeric fusion genes that modify cellular function, leading to dysregulation of proliferation and resulting in clinically and genetically distinct neoplasms. EWSR1 is a commonly rearranged gene in sarcomas that can fuse as the 5’ partner with various genes. EWSR1-rearranged sarcomas include angiomatoid fibrous histiocytoma, clear cell sarcoma of soft parts, Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), extraskeletal myxoid chondrosarcoma, myxoid liposarcoma, clear cell sarcoma-like tumors of the gastrointestinal tract, as well as round cell sarcoma with EWSR1-non-ETS fusions. Herein, we report an unusual case of EWSR1-POU5F1 fusion in an undifferentiated sarcoma. It has previously been described in myoepithelial tumors,3 but it has been described in undifferentiated sarcomas only a couple of times in the literature, to the best of our knowledge.

Move over, mouse—testing other input devices for WSIs

September 2026—As transitions to a digital pathology workflow grow in number, the question may become less about the extent to which digital slide assessment will be used in practice and more about how to work with those slides. While scanners, image management systems, and storage are most talked about, among other things, researchers at Western University in London, Ontario, turned their attention to the interface itself. They studied whether eye- and head-tracking technologies can serve as alternative input devices to hand-based input devices for digital pathology tasks.

From the President’s Desk

September 2026—From the CAP’s founding nearly 80 years ago, our organization has had a focus that sets us apart from all other pathology societies: our commitment to laboratory quality. Those of us in the U.S. are very familiar with the CAP accreditation process—which is widely considered the gold standard in laboratory accreditation—as the CAP has deemed status to accredit clinical laboratories under the U.S. Clinical Laboratory Improvement Amendments regulations.

Clinical pathology selected abstracts

September 2026—Three subtypes of inflammatory bowel disease present as chronic inflammation in children and adolescents: ulcerative colitis, Crohn’s disease, and IBD unclassified. The incidence of IBD continues to increase in pediatric populations, with a growing number of cases in preschool children. Familial patterns have been observed in 19 to 41 percent of patients, especially those younger than 11 years of age. The diagnosis of IBD is typically based on clinical presentation, endoscopic evaluation, and histological assessment of intestinal mucosa.

Anatomic pathology selected abstracts

September 2026—Autoimmune atrophic gastritis is chronic, immune-mediated inflammation restricted to the gastric body. Despite well-defined histologic features, its pathologic progression is still not fully understood. Therefore, the authors conducted a study to evaluate the pathologic progression of autoimmune atrophic gastritis. They reviewed cases with at least two follow-up biopsies.